ORNAV.HE Stock Analysis
OR
Neutral
Based on Eyestock quantitative analysis, ORNAV.HE`s fundamental data and valuation indicate an investment grade of Neutral at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Overvalued
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is headquartered in Espoo, Etela-Suomen and currently employs 3,527 full-time employees. The company went IPO on 2006-07-03. The firm is engaged in the research and development, manufacture and marketing of human and veterinary pharmaceuticals and active pharmaceutical ingredients. The core therapy areas of the Company's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases.